Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
B Asselain, W Barlow, J Bartlett, J Bergh… - The Lancet …, 2018 - thelancet.com
Background Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-
conserving surgery more feasible and might be more likely to eradicate micrometastatic …
conserving surgery more feasible and might be more likely to eradicate micrometastatic …
Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies
GK Gupta, AL Collier, D Lee, RA Hoefer, V Zheleva… - Cancers, 2020 - mdpi.com
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with …
EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung… - The Lancet, 2020 - thelancet.com
Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …
Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer
The achievement of the pathologic complete response (pCR) has been considered a metric
for the success of neoadjuvant chemotherapy (NAC) and a powerful surrogate indicator of …
for the success of neoadjuvant chemotherapy (NAC) and a powerful surrogate indicator of …
Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database
ML Plasilova, B Hayse, BK Killelea, NR Horowitz… - Medicine, 2016 - journals.lww.com
The aim of this study was to determine the features of triple-negative breast cancer (TNBC)
using a large national database. TNBC is known to be an aggressive subtype, but national …
using a large national database. TNBC is known to be an aggressive subtype, but national …
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials
P Tarantino, S Gandini, D Trapani, C Criscitiello… - Critical reviews in …, 2021 - Elsevier
Importance Several randomized trials of neoadjuvant chemo-immunotherapy in early triple
negative breast cancer (TNBC) have been recently reported, showing conflicting results …
negative breast cancer (TNBC) have been recently reported, showing conflicting results …
Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes
BL Murphy, CN Day, TL Hoskin, EB Habermann… - Annals of surgical …, 2018 - Springer
Background While breast cancer has historically been treated with surgery followed by
adjuvant chemotherapy (AC) and radiation when indicated, neoadjuvant chemotherapy …
adjuvant chemotherapy (AC) and radiation when indicated, neoadjuvant chemotherapy …
Imaging updates to breast cancer lymph node management
HL Chung, HT Le-Petross, JWT Leung - Radiographics, 2021 - pubs.rsna.org
Metastatic lymph node involvement in breast cancer is a key determinant of the overall stage
of disease and prognosis. Historically, lymph node status was determined by surgery first …
of disease and prognosis. Historically, lymph node status was determined by surgery first …
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
V Pelekanou, DE Carvajal-Hausdorf, M Altan… - Breast Cancer …, 2017 - Springer
Background The effects of neoadjuvant chemotherapy on immune markers remain largely
unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes …
unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes …
Tumor-infiltrating lymphocytes and PD-L1 expression in pre-and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial
V Pelekanou, WE Barlow, ZA Nahleh… - Molecular cancer …, 2018 - AACR
Our aim was to examine the association of pretreatment tumor-infiltrating lymphocyte (TIL)
count and PD-L1 levels with pathologic complete response (pCR) and assess immune …
count and PD-L1 levels with pathologic complete response (pCR) and assess immune …